A study from Karolinska Institutet, Stockholm, Sweden shows that MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
This study was published in the April 10, 2014 Nature [I.F >42] by Prof. Thomas H, Dr Gad H and others from Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Cancer therapy: 17-βE2 (an estrogen derivative) inhibits cancer development by suppressing the expression of nucleotide sanitizing enzyme MTH1/NUDT1. This study may suggest that 17-βE2, by up regulating its target gene, it may suppress the expression of MTH1/NUDT1. Together, this study suggests that pharmacological formulations encompassing “17-βE2 or its analogues” may be used in the treatment of human cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How 17-βE2 suppresses the expression of MTH1/NUDT1
To cite: Boominathan, Cancer therapy: 17-βE2 (an estrogen derivative) inhibits cancer development by suppressing the expression of nucleotide sanitizing enzyme MTH1/NUDT1, 08/February/2015, 14.08, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation